CORRECTION article

Front. Pharmacol., 13 December 2024

Sec. Cardiovascular and Smooth Muscle Pharmacology

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1532331

Corrigendum: (Pro)renin receptor aggravates myocardial pyroptosis in diabetic cardiomyopathy through AMPK-NLRP3 pathway

  • 1. Department of Cardiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

  • 2. National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China

  • 3. Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

  • 4. Division of Cellular and Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom

In the published article, there was an error in Figure 7 as published. In Figures 7G, J the analysis diagram for LVEF was erroneously excluded and an incorrect E/A analysis diagram was inserted in its place. The corrected Figure 7 and its caption appear below.

FIGURE 7

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

(Pro)renin receptor, diabetic cardiomyopathy, pyroptosis, NLRP3, AMPK (AMP-activated protein kinase)

Citation

Li S, Zhang J, Zhao Y, Kang L, Jie H and Dong B (2024) Corrigendum: (Pro)renin receptor aggravates myocardial pyroptosis in diabetic cardiomyopathy through AMPK-NLRP3 pathway. Front. Pharmacol. 15:1532331. doi: 10.3389/fphar.2024.1532331

Received

21 November 2024

Accepted

27 November 2024

Published

13 December 2024

Volume

15 - 2024

Edited and reviewed by

Nirmal Parajuli, Henry Ford Health System, United States

Updates

Copyright

*Correspondence: Haipeng Jie, ; Bo Dong,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics